- Males with estrogen receptor-positive/progesterone receptor-negative (ER+/PR−) breast cancer (BCa) have worse BCa-specific survival (BCSS) and worse OS than those with ER+/PR+ BCa, according to an analysis of the US Surveillance, Epidemiology, and End Results (SEER) database.
- Reasons may be larger tumor size, lymph node invasion, and metastasis at presentation.
Why this matters
- ER+/PR− tumors in males may warrant more aggressive treatment than ER+/PR+ tumors.
- Population-based retrospective cohort by Chinese researchers comparing demographics, clinical characteristics, and outcome of ER+/PR− (n=355) vs ER+/PR+ (n=2322) male BCa, using the SEER database (1990-2010).
- Funding: None.
- At diagnosis, ER+/PR− patients were younger (P=.008), were more likely African American (P<.001 and had:>
- a higher histological grade (P<.001>
- more invasion into the lymph nodes (P=.034),
- more metastasis (12.4% vs 6.5%; P<.001 and>
- later stage (P=.001).
- Retrospective, observational design.